Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 713
1.
Gut ; 69(1): 158-167, 2020 01.
Article En | MEDLINE | ID: mdl-30833451

OBJECTIVE: Hepatitis D virus (HDV) is a circular RNA virus coinfecting hepatocytes with hepatitis B virus. Chronic hepatitis D results in severe liver disease and an increased risk of liver cancer. Efficient therapeutic approaches against HDV are absent. DESIGN: Here, we combined an RNAi loss-of-function and small molecule screen to uncover host-dependency factors for HDV infection. RESULTS: Functional screening unravelled the hypoxia-inducible factor (HIF)-signalling and insulin-resistance pathways, RNA polymerase II, glycosaminoglycan biosynthesis and the pyrimidine metabolism as virus-hepatocyte dependency networks. Validation studies in primary human hepatocytes identified the carbamoyl-phosphatesynthetase 2, aspartate transcarbamylase and dihydroorotase (CAD) enzyme and estrogen receptor alpha (encoded by ESR1) as key host factors for HDV life cycle. Mechanistic studies revealed that the two host factors are required for viral replication. Inhibition studies using N-(phosphonoacetyl)-L-aspartic acid and fulvestrant, specific CAD and ESR1 inhibitors, respectively, uncovered their impact as antiviral targets. CONCLUSION: The discovery of HDV host-dependency factors elucidates the pathogenesis of viral disease biology and opens therapeutic strategies for HDV cure.


Aspartate Carbamoyltransferase/genetics , Aspartic Acid/analogs & derivatives , Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)/genetics , Dihydroorotase/genetics , Estrogen Receptor alpha/metabolism , Fulvestrant/pharmacology , Hepatitis D, Chronic/drug therapy , Phosphonoacetic Acid/analogs & derivatives , Pyrimidines/biosynthesis , Antiviral Agents/pharmacology , Aspartate Carbamoyltransferase/antagonists & inhibitors , Aspartate Carbamoyltransferase/metabolism , Aspartic Acid/pharmacology , Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)/antagonists & inhibitors , Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)/metabolism , Cell Line , Dihydroorotase/antagonists & inhibitors , Dihydroorotase/metabolism , Estrogen Receptor Antagonists/pharmacology , Estrogen Receptor alpha/antagonists & inhibitors , Gene Silencing , Hepatitis D, Chronic/genetics , Hepatitis D, Chronic/metabolism , Hepatitis Delta Virus/physiology , Hepatocytes , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Insulin Resistance , Life Cycle Stages , Loss of Function Mutation , Phosphonoacetic Acid/pharmacology , RNA Interference , RNA, Small Interfering/genetics , RNA, Viral/metabolism , Signal Transduction , Virus Replication
2.
Biochim Biophys Acta Mol Basis Dis ; 1865(9): 2180-2188, 2019 09 01.
Article En | MEDLINE | ID: mdl-31034992

Tumor microenvironment has a high concentration of inorganic phosphate (Pi), which is actually a marker for tumor progression. Regarding Pi another class of transporter has been recently studied, an H+-dependent Pi transporter, that is stimulated at acidic pH in Caco2BBE human intestinal cells. In this study, we characterized the H+-dependent Pi transport in breast cancer cell (MDA-MB-231) and around the cancer tissue. MDA-MB-231 cell line presented higher levels of H+-dependent Pi transport as compared to other breast cell lines, such as MCF-10A, MCF-7 and T47-D. The Pi transport was linear as a function of time and exhibited a Michaelis-Menten kinetic of Km = 1.387 ±â€¯0.1674 mM Pi and Vmax = 198.6 ±â€¯10.23 Pi × h-1 × mg protein-1 hence reflecting a low affinity Pi transport. H+-dependent Pi uptake was higher at acidic pH. FCCP, Bafilomycin A1 and SCH28080, which deregulate the intracellular levels of protons, inhibited the H+-dependent Pi transport. No effect on pHi was observed in the absence of inorganic phosphate. PAA, an H+-dependent Pi transport inhibitor, reduced the Pi transport activity, cell proliferation, adhesion, and migration. Arsenate, a structural analog of Pi, inhibited the Pi transport. At high Pi conditions, the H+-dependent Pi transport was five-fold higher than the Na+-dependent Pi transport, thus reflecting a low affinity Pi transport. The occurrence of an H+-dependent Pi transporter in tumor cells may endow them with an alternative path for Pi uptake in situations in which Na+-dependent Pi transport is saturated within the tumor microenvironment, thus regulating the energetically expensive tumor processes.


Phosphate Transport Proteins/metabolism , Phosphates/metabolism , Tumor Microenvironment , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cadherins/genetics , Cadherins/metabolism , Cell Adhesion , Cell Line , Cell Proliferation , Down-Regulation/drug effects , Female , Humans , Hydrogen-Ion Concentration , Ion Transport/drug effects , Kinetics , Phosphonoacetic Acid/pharmacology , Sodium-Phosphate Cotransporter Proteins, Type IIb/genetics , Sodium-Phosphate Cotransporter Proteins, Type IIb/metabolism , Up-Regulation/drug effects
3.
J Virol ; 92(19)2018 10 01.
Article En | MEDLINE | ID: mdl-30021895

Epstein-Barr virus (EBV) ZEBRA protein activates the EBV lytic cycle. Cellular AP-1 proteins with alanine-to-serine [AP-1(A/S)] substitutions homologous to ZEBRA(S186) assume some functions of EBV ZEBRA. These AP-1(A/S) mutants bind methylated EBV DNA and activate expression of some EBV genes. Here, we compare expression of 67 viral genes induced by ZEBRA versus expression induced by AP-1(A/S) proteins. AP-1(A/S) activated 24 genes to high levels and 15 genes to intermediate levels; activation of 28 genes by AP-1(A/S) was severely impaired. We show that AP-1(A/S) proteins are defective at stimulating viral lytic DNA replication. The impairment of expression of many late genes compared to that of ZEBRA is likely due to the inability of AP-1(A/S) proteins to promote viral DNA replication. However, even in the absence of detectable viral DNA replication, AP-1(A/S) proteins stimulated expression of a subgroup of late genes that encode viral structural proteins and immune modulators. In response to ZEBRA, expression of this subgroup of late genes was inhibited by phosphonoacetic acid (PAA), which is a potent viral replication inhibitor. However, when the lytic cycle was activated by AP-1(A/S), PAA did not reduce expression of this subgroup of late genes. We also provide genetic evidence, using the BMRF1 knockout bacmid, that these genes are true late genes in response to ZEBRA. AP-1(A/S) binds to the promoter region of at least one of these late genes, BDLF3, encoding an immune modulator.IMPORTANCE Mutant c-Jun and c-Fos proteins selectively activate expression of EBV lytic genes, including a subgroup of viral late genes, in the absence of viral DNA replication. These findings indicate that newly synthesized viral DNA is not invariably required for viral late gene expression. While viral DNA replication may be obligatory for late gene expression driven by viral transcription factors, it does not limit the ability of cellular transcription factors to activate expression of some viral late genes. Our results show that expression of all late genes may not be strictly dependent on viral lytic DNA replication. The c-Fos A151S mutation has been identified in a human cancer. c-Fos A151S in combination with wild-type c-Jun activates the EBV lytic cycle. Our data provide proof of principle that mutant cellular transcription factors could cause aberrant regulation of viral lytic cycle gene expression and play important roles in EBV-associated diseases.


Antigens, Viral/genetics , DNA, Viral/genetics , Herpesvirus 4, Human/genetics , Host-Pathogen Interactions , Membrane Glycoproteins/genetics , Trans-Activators/genetics , Transcription Factor AP-1/genetics , Viral Proteins/genetics , Amino Acid Substitution , Antigens, Viral/immunology , Antiviral Agents/pharmacology , Binding Sites , Cell Line, Tumor , DNA Methylation/drug effects , DNA, Viral/immunology , Gene Expression Regulation , HEK293 Cells , Herpesvirus 4, Human/drug effects , Herpesvirus 4, Human/immunology , Humans , Lymphocytes/immunology , Lymphocytes/virology , Membrane Glycoproteins/immunology , Mutation , Phosphonoacetic Acid/pharmacology , Promoter Regions, Genetic , Protein Binding , Signal Transduction , Trans-Activators/immunology , Transcription Factor AP-1/immunology , Viral Proteins/immunology , Virus Replication/drug effects
4.
Sci Rep ; 8(1): 8708, 2018 06 07.
Article En | MEDLINE | ID: mdl-29880914

Multidrug-resistant bacterial strains are a rapidly emerging healthcare threat; therefore it is critical to develop new therapies to combat these organisms. Prior antibacterial strategies directly target pathogen growth or viability. Host-directed strategies to increase antimicrobial defenses may be an effective alternative to antibiotics and reduce development of resistant strains. In this study, we demonstrated the efficacy of a pyrimidine synthesis inhibitor, N-phosphonacetyl-L-aspartate (PALA), to enhance clearance of methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Acinetobacter baumannii strains by primary human dermal fibroblasts in vitro. PALA did not have a direct bactericidal effect, but enhanced cellular secretion of the antimicrobial peptides human ß-defensin 2 (HBD2) and HBD3 from fibroblasts. When tested in porcine and human skin explant models, a topical PALA formulation was efficacious to enhance MRSA, P. aeruginosa, and A. baumannii clearance. Topical PALA treatment of human skin explants also resulted in increased HBD2 and cathelicidin (LL-37) production. The antimicrobial actions of PALA required expression of nucleotide-binding, oligomerization domain 2 (NOD2), receptor-interacting serine/threonine-protein kinase 2 (RIP2), and carbamoyl phosphatase synthase II/aspartate transcarbamylase/dihydroorotase (CAD). Our results indicate that PALA may be a new option to combat multidrug-resistant bacterial infections of the skin through enhancement of an integral pathway of the cutaneous innate immune defense system.


Aspartic Acid/analogs & derivatives , Bacteria/immunology , Dermis/immunology , Drug Resistance, Multiple, Bacterial/drug effects , Immunity, Innate/drug effects , Nod2 Signaling Adaptor Protein/immunology , Phosphonoacetic Acid/analogs & derivatives , Pyrimidines/immunology , Signal Transduction/drug effects , Skin Diseases, Bacterial/drug therapy , Animals , Aspartic Acid/pharmacology , Bacteria/pathogenicity , Dermis/microbiology , Dermis/pathology , Drug Resistance, Multiple, Bacterial/immunology , HEK293 Cells , Humans , Nod2 Signaling Adaptor Protein/metabolism , Phosphonoacetic Acid/pharmacology , Pyrimidines/biosynthesis , Signal Transduction/immunology , Skin Diseases, Bacterial/enzymology , Skin Diseases, Bacterial/immunology , Skin Diseases, Bacterial/microbiology , Swine
5.
PLoS Pathog ; 14(5): e1007070, 2018 05.
Article En | MEDLINE | ID: mdl-29813138

Late gene transcription in herpesviruses is dependent on viral DNA replication in cis but the mechanistic basis for this linkage remains unknown. DNA replication results in demethylated DNA, topological changes, removal of proteins and recruitment of proteins to promoters. One or more of these effects of DNA replication may facilitate late gene transcription. Using 5-azacytidine to promote demethylation of DNA, we demonstrate that late gene transcription cannot be rescued by DNA demethylation. Late gene transcription precedes significant increases in DNA copy number, indicating that increased template numbers also do not contribute to the linkage between replication and late gene transcription. By using serial, timed blockade of DNA replication and measurement of late gene mRNA accumulation, we demonstrate that late gene transcription requires ongoing DNA replication. Consistent with these findings, blocking DNA replication led to dissolution of DNA replication complexes which also contain RNA polymerase II and BGLF4, an EBV protein required for transcription of several late genes. These data indicate that ongoing DNA replication maintains integrity of a replication-transcription complex which is required for recruitment and retention of factors necessary for late gene transcription.


DNA Replication/physiology , Gammaherpesvirinae/genetics , Transcription, Genetic/physiology , Virus Replication/physiology , Azacitidine/pharmacology , DNA Demethylation , DNA-Directed DNA Polymerase/drug effects , Enzyme Inhibitors/pharmacology , Gammaherpesvirinae/physiology , Gene Expression Regulation, Viral/drug effects , Genes, Immediate-Early , Kinetics , Nucleic Acid Synthesis Inhibitors/pharmacology , Phosphonoacetic Acid/pharmacology , Promoter Regions, Genetic/genetics
6.
Article En | MEDLINE | ID: mdl-29723133

The pyrimidine de novo nucleotide synthesis consists of 6 sequential steps. Various inhibitors against these enzymes have been developed and evaluated in the clinic for their potential anticancer activity: acivicin inhibits carbamoyl-phosphate-synthase-II, N-(phosphonacetyl)-L- aspartate (PALA) inhibits aspartate-transcarbamylase, Brequinar sodium and dichloroallyl-lawsone (DCL) inhibit dihydroorotate-dehydrogenase, and pyrazofurin (PF) inhibits orotate-phosphoribosyltransferase. We compared their growth inhibition against 3 cell lines from head-and-neck-cancer (HEP-2, UMSCC-14B and UMSCC-14C) and related the sensitivity to their effects on nucleotide pools. In all cell lines Brequinar and PF were the most active compounds with IC50 (50% growth inhibition) values between 0.06-0.37 µM, Acivicin was as potent (IC50s 0.26-1 µM), but DCL was 20-31-fold less active. PALA was most inactive (24-128 µM). At equitoxic concentrations, all pure antipyrimidine de novo inhibitors depleted UTP and CTP after 24 hr exposure, which was most pronounced for Brequinar (between 6-10% of UTP left, and 12-36% CTP), followed by DCL and PF, which were almost similar (6-16% UTP and 12-27% CTP), while PALA was the least active compound (10-70% UTP and 13-68% CTP). Acivicin is a multi-target inhibitor of more glutamine requiring enzymes (including GMP synthetase) and no decrease of UTP was found, but a pronounced decrease in GTP (31-72% left). In conclusion, these 5 inhibitors of the pyrimidine de novo nucleotide synthesis varied considerably in their efficacy and effect on pyrimidine nucleotide pools. Inhibitors of DHO-DH were most effective suggesting a primary role of this enzyme in controlling pyrimidine nucleotide pools.


Antineoplastic Agents/pharmacology , Biphenyl Compounds/pharmacology , Carcinoma, Squamous Cell/metabolism , Head and Neck Neoplasms/metabolism , Purine Nucleotides/antagonists & inhibitors , Pyrimidine Nucleotides/antagonists & inhibitors , Ribonucleosides/pharmacology , Amides , Aspartate Carbamoyltransferase/antagonists & inhibitors , Aspartic Acid/analogs & derivatives , Aspartic Acid/pharmacology , Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)/antagonists & inhibitors , Cell Line, Tumor , Dihydroorotate Dehydrogenase , Humans , Isoxazoles/pharmacology , Naphthoquinones/pharmacology , Orotate Phosphoribosyltransferase/antagonists & inhibitors , Oxidoreductases Acting on CH-CH Group Donors/antagonists & inhibitors , Phosphonoacetic Acid/analogs & derivatives , Phosphonoacetic Acid/pharmacology , Purine Nucleotides/biosynthesis , Pyrazoles , Pyrimidine Nucleotides/biosynthesis , Ribose
7.
Langmuir ; 34(11): 3449-3458, 2018 03 20.
Article En | MEDLINE | ID: mdl-29478322

The surface modification of Fe3O4-based magnetic nanoparticles (MNPs) with N-(phosphonomethyl)iminodiacetic acid (PMIDA) was studied, and the possibility of their use as magnetic resonance imaging contrast agents was shown. The effect of the added PMIDA amount, the reaction temperature and time on the degree of immobilization of this reagent on MNPs, and the hydrodynamic characteristics of their aqueous colloidal solutions have been systematically investigated for the first time. It has been shown that the optimum condition for the modification of MNPs is the reaction at 40 °C with an equimolar amount of PMIDA for 3.5 h. The modified MNPs were characterized by X-ray diffraction, transmission electron microscopy, Fourier transform infrared spectroscopy, thermogravimetric, and CHN elemental analyses. The dependence of the hydrodynamic characteristics of the MNP colloidal solutions on the concentration and pH of the medium was studied by the dynamic light scattering method. On the basis of the obtained data, we can assume that the PMIDA molecules are fixed on the surface of the MNPs as a monomolecular layer. The modified MNPs had good colloidal stability and high magnetic properties. The calculated relaxivities r2 and r1 were 341 and 102 mmol-1 s-1, respectively. The possibility of using colloidal solutions of PMIDA-modified MNPs as a T2 contrast agent for liver studies in vivo (at a dose of 0.6 mg kg-1) was demonstrated for the first time.


Contrast Media/pharmacology , Liver/metabolism , Magnetite Nanoparticles/chemistry , Phosphonoacetic Acid/analogs & derivatives , Animals , CHO Cells , Cell Line, Tumor , Contrast Media/chemistry , Contrast Media/toxicity , Cricetulus , Humans , Magnetic Resonance Imaging/methods , Magnetite Nanoparticles/toxicity , Male , Mesocricetus , Phosphonoacetic Acid/chemistry , Phosphonoacetic Acid/pharmacology , Phosphonoacetic Acid/toxicity , Temperature
8.
J Enzyme Inhib Med Chem ; 33(1): 384-389, 2018 Dec.
Article En | MEDLINE | ID: mdl-29372656

Small molecule inhibitors have a powerful blocking action on viral polymerases. The bioavailability of the inhibitor, nevertheless, often raise a significant selectivity constraint and may substantially limit the efficacy of therapy. Phosphonoacetic acid has long been known to possess a restricted potential to block DNA biosynthesis. In order to achieve a better affinity, this compound has been linked with natural nucleotide at different positions. The structural context of the resulted conjugates has been found to be crucial for the acquisition by DNA polymerases. We show that nucleobase-conjugated phosphonoacetic acid is being accepted, but this alters the processivity of DNA polymerases. The data presented here not only provide a mechanistic rationale for a switch in the mode of DNA synthesis, but also highlight the nucleobase-targeted nucleotide functionalization as a route for enhancing the specificity of small molecule inhibitors.


DNA-Directed DNA Polymerase/metabolism , Enzyme Inhibitors/pharmacology , Nucleotides/pharmacology , Phosphonoacetic Acid/pharmacology , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , HIV-1/enzymology , Molecular Structure , Moloney murine leukemia virus/enzymology , Nucleotides/chemistry , Phosphonoacetic Acid/chemical synthesis , Phosphonoacetic Acid/chemistry
9.
Virol J ; 14(1): 221, 2017 11 13.
Article En | MEDLINE | ID: mdl-29132393

BACKGROUND: Epstein-Barr virus (EBV) exhibits both lytic and latent (Lat. I, II, and III) phases in an infected individual. It's during the latent phase of EBV that all EBV-associated cancers, including Burkitt's lymphoma, nasopharyngeal carcinoma and lymphoproliferative disease arise. Interferon-γ-inducible protein 16 (IFI16) is a well-established innate immune sensor and viral transcriptional regulator involved in response to invading DNA viruses. During latency, IFI16 remains in the nucleus, in part bound to the EBV genome; however, neither its role in EBV lytic cycle or latency has been established. METHODS: Short interfering RNA against IFI16 and IFI16 overexpression were used to identify the role of IFI16 in the maintenance of EBV latency I. We also studied how induction of the lytic cycle affected IFI16 using the EBV positive, latently infected Akata or MUTU-1 cell lines. Akata cells were induced with TPA and MUTU-1 cells with TGF-ß up to 96 h and changes in IFI16 protein were analyzed by Western blotting and immunofluorescence microscopy. To assess the mechanism of IFI16 decrease, EBV DNA replication and late lytic transcripts were blocked using the viral DNA polymerase inhibitor phosphonoacetic acid. RESULTS: Knockdown of IFI16 mRNA by siRNA resulted in enhanced levels of EBV lytic gene expression from all temporal gene classes, as well as an increase in the total EBV genome abundance, whereas overexpression of exogenous IFI16 reversed these effects. Furthermore, 96 h after induction of the lytic cycle with either TPA (Akata) or TGF-ß (MUTU-1), IFI16 protein levels decreased up to 80% as compared to the EBV-negative cell line BJAB. Reduction in IFI16 was observed in cells expressing EBV lytic envelope glycoprotein. The decreased levels of IFI16 protein do not appear to be dependent on late lytic transcripts of EBV but suggest involvement of the immediate early, early, or a combination of both gene classes. CONCLUSIONS: Reduction of IFI16 protein levels following lytic cycle induction, as well as reactivation from latency after IFI16 mRNA knockdown suggests that IFI16 is crucial for the maintenance of EBV latency. More importantly, these results identify IFI16 as a unique host factor protein involved in the EBV lifecycle, making it a potential therapeutic target to combat EBV-related malignancies.


Epstein-Barr Virus Infections/genetics , Epstein-Barr Virus Infections/virology , Herpesvirus 4, Human/physiology , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Phosphoproteins/genetics , Phosphoproteins/metabolism , Virus Latency/genetics , Burkitt Lymphoma/genetics , Burkitt Lymphoma/virology , Cell Line, Tumor , Gene Expression Regulation/drug effects , Gene Knockdown Techniques , Genome, Viral/genetics , Herpesvirus 4, Human/genetics , Host-Pathogen Interactions , Humans , Phosphonoacetic Acid/pharmacology , Tetradecanoylphorbol Acetate/pharmacology , Transforming Growth Factor beta/pharmacology , Viral Proteins/genetics , Virus Activation/genetics
10.
Chem Res Toxicol ; 30(11): 1984-1992, 2017 11 20.
Article En | MEDLINE | ID: mdl-28872853

The bacteriophage T4 DNA polymerase (pol) and the closely related RB69 DNA pol have been developed into model enzymes to study family B DNA pols. While all family B DNA pols have similar structures and share conserved protein motifs, the molecular mechanism underlying natural drug resistance of nonherpes family B DNA pols and drug sensitivity of herpes DNA pols remains unknown. In the present study, we constructed T4 phages containing G466S, Y460F, G466S/Y460F, P469S, and V475W mutations in DNA pol. These amino acid substitutions replace the residues in drug-resistant T4 DNA pol with residues found in drug-sensitive herpes family DNA pols. We investigated whether the T4 phages expressing the engineered mutant DNA pols were sensitive to the antiviral drug phosphonoacetic acid (PAA) and characterized the in vivo replication fidelity of the phage DNA pols. We found that G466S substitution marginally increased PAA sensitivity, whereas Y460F substitution conferred resistance. The phage expressing a double mutant G466S/Y460F DNA pol was more PAA-sensitive. V475W T4 DNA pol was highly sensitive to PAA, as was the case with V478W RB69 DNA pol. However, DNA replication was severely compromised, which resulted in the selection of phages expressing more robust DNA pols that have strong ability to replicate DNA and contain additional amino acid substitutions that suppress PAA sensitivity. Reduced replication fidelity was observed in all mutant phages expressing PAA-sensitive DNA pols. These observations indicate that PAA sensitivity and fidelity are balanced in DNA pols that can replicate DNA in different environments.


Antiviral Agents/pharmacology , Bacteriophage T4/drug effects , Bacteriophage T4/enzymology , DNA-Directed DNA Polymerase/metabolism , Phosphonoacetic Acid/pharmacology , Amino Acid Sequence , Amino Acid Substitution , Bacteriophage T4/chemistry , Bacteriophage T4/genetics , DNA Replication/drug effects , DNA-Directed DNA Polymerase/chemistry , DNA-Directed DNA Polymerase/genetics , Models, Molecular , Point Mutation , Sequence Alignment
11.
Structure ; 24(7): 1081-94, 2016 07 06.
Article En | MEDLINE | ID: mdl-27265852

CAD, the multienzymatic protein that initiates and controls de novo synthesis of pyrimidines in animals, associates through its aspartate transcarbamoylase (ATCase) domain into particles of 1.5 MDa. Despite numerous structures of prokaryotic ATCases, we lack structural information on the ATCase domain of CAD. Here, we report the structure and functional characterization of human ATCase, confirming the overall similarity with bacterial homologs. Unexpectedly, human ATCase exhibits cooperativity effects that reduce the affinity for the anti-tumoral drug PALA. Combining structural, mutagenic, and biochemical analysis, we identified key elements for the necessary regulation and transmission of conformational changes leading to cooperativity between subunits. Mutation of one of these elements, R2024, was recently found to cause the first non-lethal CAD deficit. We reproduced this mutation in human ATCase and measured its effect, demonstrating that this arginine is part of a molecular switch that regulates the equilibrium between low- and high-affinity states for the ligands.


Aspartate Carbamoyltransferase/chemistry , Antineoplastic Agents/pharmacology , Aspartate Carbamoyltransferase/antagonists & inhibitors , Aspartate Carbamoyltransferase/metabolism , Aspartic Acid/analogs & derivatives , Aspartic Acid/pharmacology , Catalytic Domain , Enzyme Inhibitors/pharmacology , Humans , Phosphonoacetic Acid/analogs & derivatives , Phosphonoacetic Acid/pharmacology
12.
Int J Oncol ; 47(2): 782-90, 2015 Aug.
Article En | MEDLINE | ID: mdl-26058363

Drug resistance is a major obstacle in successful systemic therapy of metastatic cancer. We analyzed the involvement of cell cycle regulatory proteins in eliciting response to N (phosphonoacetyl)-L-aspartate (PALA), an inhibitor of de novo pyrimidine synthesis, in two metastatic variants of human cancer cell line MDA-MB-435 isolated from lung (L-2) and brain (Br-1) in nude mouse, respectively. L-2 and Br-l cells markedly differed in their sensitivity to PALA. While both cell types displayed an initial S phase delay/arrest, Br-l cells proliferated but most L-2 cells underwent apoptosis. There was distinct elevation in cyclin A, and phosphorylated Rb proteins concomitant with decreased expression of bcl-2 protein in the PALA treated L-2 cells undergoing apoptosis. Markedly elevated cyclin A associated and cdk2 kinase activities together with increased E2F1-DNA binding were detected in these L-2 cells. Induced ectopic cyclin A expression sensitized Br-l cells to PALA by activating an apoptotic pathway. Our findings demonstrate that elevated expression of cyclin A and associated kinase can activate an apoptotic pathway in cells exposed to DNA antimetabolites. Abrogation of this pathway can lead to resistance against these drugs in metastatic variants of human carcinoma cells.


Antimetabolites, Antineoplastic/pharmacology , Aspartic Acid/analogs & derivatives , Brain Neoplasms/secondary , Cyclin A/metabolism , Cyclin-Dependent Kinase 2/metabolism , Lung Neoplasms/secondary , Phosphonoacetic Acid/analogs & derivatives , Animals , Apoptosis , Aspartic Acid/pharmacology , Brain Neoplasms/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Drug Resistance, Neoplasm/drug effects , Humans , Lung Neoplasms/metabolism , Mice , Mice, Nude , Phosphonoacetic Acid/pharmacology , Up-Regulation
13.
J Proteome Res ; 12(4): 1820-9, 2013 Apr 05.
Article En | MEDLINE | ID: mdl-23418649

Herpesviruses are among the most complex and widespread human viruses and cause a number of diseases ranging from cold sores to genital infections and encephalitis. While the composition of viral particles has been studied, less is known about the expression of the whole viral proteome in infected cells. Here, we analyzed the proteome of the prototypical Herpes Simplex Virus type 1 (HSV1) in infected cells by mass spectrometry. Using a high sensitivity LTQ-Orbitrap, we achieved a very high level of protein coverage and identified a total of 67 structural and nonstructural viral proteins. We also identified 90 novel phosphorylation sites and 10 novel ubiquitylation sites on different viral proteins. Ubiquitylation was observed on nine HSV1 proteins. We identified phosphorylation sites on about half of the detected viral proteins; many of the highly phosphorylated ones are known to regulate gene expression. Treatment with inhibitors of DNA replication induced changes of both viral protein abundance and modifications, highlighting the interdependence of viral proteins during the life cycle. Given the importance of expression dynamics, ubiquitylation, and phosphorylation for protein function, these findings will serve as important tools for future studies on herpesvirus biology.


Herpesvirus 1, Human/metabolism , Viral Proteins/metabolism , Acyclovir/pharmacology , Animals , Antiviral Agents/pharmacology , Cell Line/virology , Cycloheximide/pharmacology , DNA Replication/drug effects , Gene Expression Regulation, Viral , Herpesvirus 1, Human/drug effects , Herpesvirus 1, Human/genetics , Macrophages/virology , Mice , Mice, Inbred C57BL , Phosphonoacetic Acid/pharmacology , Phosphorylation , Protein Processing, Post-Translational , Protein Transport , Proteomics/methods , Ubiquitination , Viral Nonstructural Proteins/metabolism , Viral Proteins/genetics
14.
Oncogene ; 32(7): 920-9, 2013 Feb 14.
Article En | MEDLINE | ID: mdl-22430213

p53 is essential for the cellular responses to DNA damage that help to maintain genomic stability. However, the great majority of human cancers undergo disruption of the p53-network. Identification and characterization of molecular components important in both p53-dependent and -independent apoptosis might be useful in developing novel therapies for cancers. In the complete absence of p53, cells treated with N-(phosphonacetyl)-L-aspartate (PALA) continue to synthesize DNA slowly and eventually progress through S-phase, suffering severe DNA damage that in turn triggers apoptosis, whereas cells with functional p53 undergo growth arrest. In this study, we investigated apoptotic signaling in response to PALA and the role of p53 expression in this pathway. We found that treatment of cells lacking p53 with PALA induced TAp73, Noxa and Bim and inactivation of these proteins with dominant-negative plasmids or small interfering RNAs significantly inhibited apoptosis, suggesting that PALA-induced apoptosis was mediated via TAp73-dependent expression of Noxa and Bim. However, PALA treatment inhibited the expression of ΔNp73 only in cells lacking p53 but not in cells expressing p53. In addition, PALA treatment inhibited Bcl-2, and overexpression of Bcl-2 significantly inhibited PALA-induced apoptosis. Moreover, expression of p53 in these cells protected them from PALA-induced apoptosis by activating p21, sustaining the expression of ΔNp73 and inhibiting the induction of Noxa and Bim. Taken together, our study identifies novel but opposing roles for the p53 and TAp73 in the induction of Noxa and Bim and regulation of apoptosis. Our data will help to develop strategies to eliminate cancer cells lacking p53 while protecting normal cells with wild-type p53.


Apoptosis/drug effects , Aspartic Acid/analogs & derivatives , DNA-Binding Proteins/physiology , Neoplasms/drug therapy , Nuclear Proteins/physiology , Phosphonoacetic Acid/analogs & derivatives , Proto-Oncogene Proteins c-bcl-2/genetics , Tumor Suppressor Proteins/physiology , Antimetabolites, Antineoplastic/pharmacology , Antimetabolites, Antineoplastic/therapeutic use , Apoptosis/genetics , Apoptosis Regulatory Proteins/genetics , Apoptosis Regulatory Proteins/metabolism , Aspartic Acid/pharmacology , Aspartic Acid/therapeutic use , Bcl-2-Like Protein 11 , Cells, Cultured , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Drug Evaluation, Preclinical , Gene Expression Regulation/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Humans , Membrane Proteins/genetics , Membrane Proteins/metabolism , Neoplasms/genetics , Neoplasms/metabolism , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Phosphonoacetic Acid/pharmacology , Phosphonoacetic Acid/therapeutic use , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Tumor Protein p73 , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Protein p53/physiology , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolism , Up-Regulation/drug effects
15.
Biochem Biophys Res Commun ; 427(3): 473-7, 2012 Oct 26.
Article En | MEDLINE | ID: mdl-22975353

BACKGROUND: Hyperthermia plays an important role in cancer therapy. However, as with radiation, it can cause DNA damage and therefore genetic instability. We studied whether hyperthermia can induce gene amplification in cancer cells and explored potential underlying molecular mechanisms. MATERIALS AND METHODS: (1) Hyperthermia: HCT116 colon cancer cells received water-submerged heating treatment at 42 or 44°C for 30 min; (2) gene amplification assay using N-(phosphoacetyl)-L-aspartate (PALA) selection of cabamyl-P-synthetase, aspartate transcarbarmylase, dihydro-orotase (cad) gene amplified cells; (3) southern blotting for confirmation of increased cad gene copies in PALA-resistant cells; (4) γH2AX immunostaining to detect γH2AX foci as an indication for DNA double strand breaks. RESULTS: (1) Heat exposure at 42 or 44°C for 30 min induces gene amplification. The frequency of cad gene amplification increased by 2.8 and 6.5 folds respectively; (2) heat exposure at both 42 and 44°C for 30 min induces DNA double strand breaks in HCT116 cells as shown by γH2AX immunostaining. CONCLUSION: This study shows that heat exposure can induce gene amplification in cancer cells, likely through the generation of DNA double strand breaks, which are believed to be required for the initiation of gene amplification. This process may be promoted by heat when cellular proteins that are responsible for checkpoints, DNA replication, DNA repair and telomere functions are denatured. To our knowledge, this is the first study to provide direct evidence of hyperthermia induced gene amplification.


Gene Amplification , Gene Expression Regulation, Neoplastic , Hot Temperature/adverse effects , Hyperthermia, Induced/adverse effects , Neoplasms/genetics , Neoplasms/therapy , Acid Anhydride Hydrolases/genetics , Aspartate Carbamoyltransferase/genetics , Aspartic Acid/analogs & derivatives , Aspartic Acid/pharmacology , DNA Breaks, Double-Stranded , Dihydroorotase/genetics , HCT116 Cells , Humans , Phosphonoacetic Acid/analogs & derivatives , Phosphonoacetic Acid/pharmacology , Acylphosphatase
16.
Nature ; 488(7411): 337-42, 2012 Aug 16.
Article En | MEDLINE | ID: mdl-22895339

Inactivation of tumour-suppressor genes by homozygous deletion is a prototypic event in the cancer genome, yet such deletions often encompass neighbouring genes. We propose that homozygous deletions in such passenger genes can expose cancer-specific therapeutic vulnerabilities when the collaterally deleted gene is a member of a functionally redundant family of genes carrying out an essential function. The glycolytic gene enolase 1 (ENO1) in the 1p36 locus is deleted in glioblastoma (GBM), which is tolerated by the expression of ENO2. Here we show that short-hairpin-RNA-mediated silencing of ENO2 selectively inhibits growth, survival and the tumorigenic potential of ENO1-deleted GBM cells, and that the enolase inhibitor phosphonoacetohydroxamate is selectively toxic to ENO1-deleted GBM cells relative to ENO1-intact GBM cells or normal astrocytes. The principle of collateral vulnerability should be applicable to other passenger-deleted genes encoding functionally redundant essential activities and provide an effective treatment strategy for cancers containing such genomic events.


Brain Neoplasms/drug therapy , Brain Neoplasms/genetics , Genes, Essential/genetics , Glioblastoma/drug therapy , Glioblastoma/genetics , Molecular Targeted Therapy/methods , Sequence Deletion/genetics , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor/deficiency , Biomarkers, Tumor/genetics , Brain Neoplasms/pathology , Cell Line, Tumor , Cell Proliferation , Chromosomes, Human, Pair 1/genetics , DNA-Binding Proteins/deficiency , DNA-Binding Proteins/genetics , Enzyme Inhibitors , Gene Expression Regulation, Neoplastic , Gene Knockdown Techniques , Genes, Tumor Suppressor , Glioblastoma/pathology , Homozygote , Humans , Hydroxamic Acids/pharmacology , Hydroxamic Acids/therapeutic use , Mice , Neoplasm Transplantation , Phosphonoacetic Acid/analogs & derivatives , Phosphonoacetic Acid/pharmacology , Phosphonoacetic Acid/therapeutic use , Phosphopyruvate Hydratase/antagonists & inhibitors , Phosphopyruvate Hydratase/deficiency , Phosphopyruvate Hydratase/genetics , Phosphopyruvate Hydratase/metabolism , RNA, Small Interfering/genetics , Tumor Suppressor Proteins/deficiency , Tumor Suppressor Proteins/genetics
17.
J Neurovirol ; 18(3): 231-43, 2012 Jun.
Article En | MEDLINE | ID: mdl-22581427

Infection of permissive cells, in tissue culture, with herpes simplex virus (HSV) has been reported to induce host DNA damage repair responses that are necessary for efficient viral replication. However, direct repair of the damaged viral DNA has not, to our knowledge, been shown. In this report, we detect and determine the amount of damaged HSV-1 DNA, following introduction of experimentally damaged HSV genomes into tissue cultures of permissive Vero, NGF differentiated PC12 cells and primary rat neurons, using a method of detection introduced here. The results show that HSV-1 strain 17 DNA containing UV-induced DNA damage is efficiently repaired, in Vero, but not NGF differentiated PC12 cells. The primary rat neuronal cultures were capable of repairing the damaged viral DNA, but with much less efficiency than did the permissive Vero cells. Moreover, by conducting the experiments with either an inhibitor of the HSV polymerase (phosphonoacetic acid [PAA]) or with a replication defective DNA polymerase mutant virus, HP66, the results suggest that repair can occur in the absence of a functional viral polymerase, although polymerase function seems to enhance the efficiency of the repair, in a replication independent manner. The possible significance of varying cell type mediated repair of viral DNA to viral pathogenesis is discussed.


DNA Damage , DNA Repair , DNA, Viral/metabolism , Herpes Simplex/metabolism , Neurons/metabolism , Simplexvirus/genetics , Animals , Chlorocebus aethiops , DNA, Viral/genetics , DNA, Viral/radiation effects , DNA-Directed DNA Polymerase/genetics , DNA-Directed DNA Polymerase/metabolism , Enzyme Inhibitors/pharmacology , Herpes Simplex/genetics , Herpes Simplex/virology , Host Specificity , Host-Pathogen Interactions , Neurons/pathology , Neurons/virology , Nucleic Acid Synthesis Inhibitors , PC12 Cells , Phosphonoacetic Acid/pharmacology , Primary Cell Culture , Rats , Simplexvirus/metabolism , Ultraviolet Rays , Vero Cells , Virus Replication
18.
Org Biomol Chem ; 10(4): 746-54, 2012 Jan 28.
Article En | MEDLINE | ID: mdl-22124653

Chimeric 2'-O-methyl oligoribonucleotides (2'-OMe ORNs) containing internucleotide linkages which were modified with phosphonoacetate (PACE) or thiophosphonoacetate (thioPACE) were prepared by solid-phase synthesis. The modified 2'-OMe ORNs contained a central phosphate or phosphorothioate sequence with up to 4 PACE or thioPACE modifications, respectively, at either end of the ORN in a "gapmer" motif. Both PACE and thioPACE 2'-OMe ORNs formed stable duplexes with complementary RNA. The majority of these duplexes had higher thermal melting temperatures than an unmodified RNA:RNA duplex. The modified 2'-OMe ORNs were effective passenger strands with complementary, unmodified siRNAs, for inducing siRNA activity in a dual luciferase assay in the presence of a lipid transfecting agent. As single strands, thioPACE 2'-OMe ORNs were efficiently taken up by HeLa cells in the absence of a lipid transfecting agent. Furthermore, thioPACE modifications greatly improved the potency of a 2'-OMe phosphorothioate ORN as an inhibitor of microRNA-122 in Huh7 cells, without lipid transfection.


Oligoribonucleotides/chemistry , Oligoribonucleotides/pharmacology , Phosphonoacetic Acid/chemistry , Phosphonoacetic Acid/pharmacology , Base Sequence , Cell Line , HeLa Cells , Humans , MicroRNAs/antagonists & inhibitors , Oligoribonucleotides/chemical synthesis , Oligoribonucleotides/pharmacokinetics , Phosphonoacetic Acid/chemical synthesis , Phosphonoacetic Acid/pharmacokinetics , RNA, Small Interfering/pharmacology , Solid-Phase Synthesis Techniques , Sulfhydryl Compounds/chemical synthesis , Sulfhydryl Compounds/chemistry , Sulfhydryl Compounds/pharmacokinetics , Sulfhydryl Compounds/pharmacology
19.
Comp Immunol Microbiol Infect Dis ; 35(2): 103-15, 2012 Mar.
Article En | MEDLINE | ID: mdl-22195977

The kinetics of expression of only a few genes of infectious laryngotracheitis virus (ILTV) have been determined, using northern blot analysis. We used quantitative reverse transcriptase PCR to examine the kinetics of expression of 74 ILTV genes in LMH cells. ICP4 was the only gene fully expressed in the presence of cycloheximide, and thus classified as immediate-early. The genes most highly expressed early in infection, and thus classified as early, included UL1 (gL), UL2, UL3, UL4, UL5, UL6, UL7, UL8, UL13, UL14, UL19, UL20, UL23 (TK), UL25, UL28, UL29, UL31, UL33, UL34, UL38, UL39, UL40, UL42, UL43, UL44 (gC), UL47, UL48 (α-TIF), UL49, UL54 (ICP27), US3 and US10. ORF A, ORF B, ORF C, ORF E, sORF 4/3, UL[-1], UL0, UL3.5, UL9, UL10 (gM), UL11, UL15a, UL15b, UL18, UL22 (gH), UL24, UL26, UL30, UL32, UL36, UL45, UL49.5 (gN), UL52, US2, US4 (gG), US5 (gJ) and US9 were most highly expressed late in infection and were thus considered late genes. Several genes, including ORF D, UL12, UL17, UL21, UL27 (gB), UL35, UL37, UL41, UL46, UL50, UL51, UL53 (gK), US8 (gE), US6 (gD) and US7 (gI), had features of both early and late genes and were classified as early/late. Our findings suggest transcription from most of ILTV genes is leaky or subject to more complex patterns of regulation than those classically described for herpesviruses. This is the first study examining global expression of ILTV genes and the data provide a basis for future investigations of the pathogenesis of infection with ILTV.


Genes, Viral , Herpesvirus 1, Gallid/genetics , Transcription, Genetic , Animals , Antiviral Agents/pharmacology , Chick Embryo , Gene Expression Regulation, Viral/drug effects , Kinetics , Phosphonoacetic Acid/pharmacology , Transcription, Genetic/drug effects
20.
Biochemistry ; 50(45): 9694-707, 2011 Nov 15.
Article En | MEDLINE | ID: mdl-21958066

While crystallographic structures of the R. etli pyruvate carboxylase (PC) holoenzyme revealed the location and probable positioning of the essential activator, Mg(2+), and nonessential activator, acetyl-CoA, an understanding of how they affect catalysis remains unclear. The current steady-state kinetic investigation indicates that both acetyl-CoA and Mg(2+) assist in coupling the MgATP-dependent carboxylation of biotin in the biotin carboxylase (BC) domain with pyruvate carboxylation in the carboxyl transferase (CT) domain. Initial velocity plots of free Mg(2+) vs pyruvate were nonlinear at low concentrations of Mg(2+) and a nearly complete loss of coupling between the BC and CT domain reactions was observed in the absence of acetyl-CoA. Increasing concentrations of free Mg(2+) also resulted in a decrease in the K(a) for acetyl-CoA. Acetyl phosphate was determined to be a suitable phosphoryl donor for the catalytic phosphorylation of MgADP, while phosphonoacetate inhibited both the phosphorylation of MgADP by carbamoyl phosphate (K(i) = 0.026 mM) and pyruvate carboxylation (K(i) = 2.5 mM). In conjunction with crystal structures of T882A R. etli PC mutant cocrystallized with phosphonoacetate and MgADP, computational docking studies suggest that phosphonoacetate could coordinate to one of two Mg(2+) metal centers in the BC domain active site. Based on the pH profiles, inhibition studies, and initial velocity patterns, possible mechanisms for the activation, regulation, and coordination of catalysis between the two spatially distinct active sites in pyruvate carboxylase from R. etli by acetyl-CoA and Mg(2+) are described.


Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/metabolism , Pyruvate Carboxylase/antagonists & inhibitors , Pyruvate Carboxylase/metabolism , Rhizobium etli/enzymology , Acetyl Coenzyme A/metabolism , Acetyl Coenzyme A/pharmacology , Adenosine Diphosphate/metabolism , Adenosine Triphosphate/metabolism , Bacterial Proteins/chemistry , Bacterial Proteins/genetics , Catalytic Domain , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Hydrogen-Ion Concentration , Kinetics , Magnesium/metabolism , Magnesium/pharmacology , Mutagenesis, Site-Directed , Oxaloacetic Acid/metabolism , Phosphonoacetic Acid/pharmacology , Phosphorylation , Protein Structure, Tertiary , Pyruvate Carboxylase/chemistry , Pyruvate Carboxylase/genetics , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Rhizobium etli/genetics
...